Orbimed Advisors Llc - Jan 11, 2022 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role: Director, 10%+ Owner
Signature: /s/ Carl Gordon, Member of OrbiMed Advisors LLC
Stock symbol: THRX
Transactions as of: Jan 11, 2022
Transactions value $: $442,750
Form type: 4
Date filed: 1/13/2022, 06:18 PM
Previous filing: Dec 30, 2021
Next filing: Jan 20, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	THRX	Common Stock	Purchase	$15.7K	+1.6K	+0.01%	$9.81	16.3M	Jan 11, 2022	See Footnotes	F1, F2, F7
transaction	THRX	Common Stock	Purchase	$73.6K	+6.9K	+0.04%	$10.67	16.3M	Jan 11, 2022	See Footnotes	F2, F3, F7
transaction	THRX	Common Stock	Purchase	$190K	+18.9K	+0.12%	$10.06	16.4M	Jan 12, 2022	See Footnotes	F2, F4, F7
transaction	THRX	Common Stock	Purchase	$163K	+17.3K	+0.11%	$9.43	16.4M	Jan 13, 2022	See Footnotes	F2, F5, F7
holding	THRX	Common Stock						499K	Jan 11, 2022	See Footnotes	F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of the Issuer's common stock ("Shares") were purchased in a block order at price of $9.81.
F2	The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
F3	These Shares were purchased in a block order at price of $10.67.
F4	These Shares were purchased in a block order at price of $10.06.
F5	These Shares were purchased in a block order at price of $9.43.
F6	The shares are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
F7	Each of GP VII, Genesis GP, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.